# Regulatory Writing Portfolio – Rinvoq (Upadacitinib)

This repository contains sample **Common Technical Document (CTD) Module 1-5 sections** prepared as part of a regulatory writing portfolio project.  
The drug selected is **Upadacitinib (Rinvoq®)**, a selective JAK1 inhibitor approved for multiple autoimmune conditions.

## 📂 Contents
- **ectd-rinvoq.pdf** – Combined document containing the drafted CTD sections.
- **2.3 Quality Overall Summary (QOS)** – Summary of Chemistry, Manufacturing, and Controls (CMC).
- **2.5 Clinical Overview** – High-level summary of clinical development, safety, and efficacy.
- **2.7 Clinical Summaries** – Detailed summaries of clinical pharmacology, efficacy, and safety data.

## 🧾 Purpose
- Demonstrate ability to author and compile regulatory documents in compliance with **ICH M4 CTD format**.
- Showcase clarity, structure, and scientific writing skills relevant to **regulatory submissions**.
- Provide a portfolio sample for prospective employers and collaborators.

## ⚠️ Disclaimer
This project is for **educational and portfolio purposes only**.  
It is a **mock regulatory submission** based on publicly available information and academic knowledge.  
It does not represent official AbbVie documents or confidential regulatory filings.

---

👩‍💻 Author: Sakshi Vashisth  
📌 Created as part of a **Regulatory Writing Portfolio Project (2025)**
